Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...

Dive into a comprehensive exploration of the latest trends and cutting-edge strategies in medical publication planning. Our ...

Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, won the ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...

The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...